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Abstract
Approximately 25.8 million Americans have been diagnosed with diabetes, and
an additional 57 million Americans are estimated to have pre-diabetes. The prevalence of
diabetes is expected to double by the year 2050. The seventh leading cause of death in
the United States, diabetes costs have risen to $174 billion annually, and diabetes is
associated with a twofold to fourfold increase in risk of cardiovascular disease. The
management of diabetic dyslipidemia (particularly LDL-C), a highly modifiable and
widely recognized risk factor, is a key component in a multifaceted approach to
preventing the development of cardiovascular disease. The National Institute of Health
has published guidelines for primary care providers to follow in the monitoring and
management of dyslipidemia in patients with type 2 diabetes. The purpose of this study
was to identify patient care practices of primary care providers in the monitoring and
management of dyslipidemia in patients with type 2 diabetes according to the third report
of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III).
The study presented here was a retrospective chart review of 300 charts completed in
three primary care clinics in a southeastern state. The participants who were chosen, ages
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18-65 years, had a diagnosis of type 2 diabetes and dyslipidemia. The research questions
posed in this study evaluated the monitoring and treatment of lipid levels in the type 2
diabetic patient. Nola Pender's Health Promotion Model provided the theoretical
framework of this study. A descriptive quantitative design was applied using a data
collection worksheet targeting specific data from the chart. The data were analyzed using
descriptive statistics and the chi-square test. Of the charts reviewed, only 21% of
participants had LDL-C levels at goal level (< 100 mg/dL), suggesting that healthcare
providers are not in compliance with the NCEP ATP III guidelines. Other findings from
the study revealed that the majority of participants were receiving lipid-lowering drugs,
mostly statin therapy. Eighty-two percent of participants received TLC instruction and
100% of participants were compliant in scheduling follow-up appointments in accordance
with the NCEP ATP III guidelines.
The results of the study revealed that healthcare providers are initiating treatment,
educating on therapeutic lifestyle changes, and following up with patients appropriately.
However, healthcare providers are failing to adjust medications to achieve the goal of
LDL-C levels set by the NCEP ATP III guidelines.
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CHAPTER I
Dimensions of the Problem
Significance of the Study
Uncontrolled diabetes leads to an increase in co-morbidities, an increase in
healthcare costs, and an increase in mortality. Primary care providers are on the front
line of lowering these figures for each diabetic patient. According to the National
Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines,
only one third of treated patients are achieving their LDL goal. This lack of adherence is
causing these patients to miss the risk-reducing benefit of treatment and creating
enormous costs in the healthcare system to treat cardiovascular events that may have
been preventable. By detecting any areas of weakness, the study aims to promote greater
adherence to current guidelines. In turn, this awareness will benefit patients by achieving
better standards of care.
Theoretical Framework
Nola Pender's Health Promotion Model (HPM) was utilized as the framework of
this study. Pender's HPM defines health as a "positive dynamic state not merely the
absence of disease" which clearly coincides with the preventative nature of the current
research topic (George, 2011, p. 551). The HPM also acknowledges the multi
dimensional nature of the individual person, encompassing the role of the healthcare
provider. The main goal of the model focuses on increasing each individual's level of
well-being. Three highlighted areas of the HPM include the individual's
characteristics/experiences, behavior-specific cognitions and affect, and behavioral
outcomes. Through nursing actions, these variables can be modified to promote optimal
well-being (George, 2011).
1

The HPM acknowledges that although the healthcare professional has a direct
influence on the individual, as a part of the individual's interpersonal sphere, the
individual must take the first step in self-initiative toward a behavioral change. Another
important factor to consider is that the individual is in a constant state of adaptation. The
healthcare professional must be willing to recognize this influence and modify
accordingly (George, 2011).
The factors that are predictive of a specified behavioral change include personal
biological factors, personal psychological factors, and personal sociocultural factors.
Personal biological factors include age, gender, and body mass index. Personal
psychological factors include self-esteem, self-motivation, perceived health status, and
definition of health. Personal sociocultural factors include race, ethnicity, education, and
socioeconomic status. These factors must be incorporated into each healthcare
professional's scope when promoting a behavioral change (George, 2011).
The current researchers utilized this theory to view the primary care provider's
effectiveness in treating each diabetic patient with dyslipidemia. As a member of the
individual's interpersonal sphere, the primary care provider holds a powerful position of
influence. The purpose behind management of dyslipidemia in diabetic patients is to
decrease the chances that the individual will develop harmful health consequences.
Pender's HPM provided a theory the researchers used to guide the current study. The
role of the primary care provider is utilized in the model in guiding the individual toward
the health-promoting behavior of lipid-lowering. The model also allowed the researchers
to view each individual from a holistic vantage point and to take into account the
influences and barriers impacting the success of this health-promoting behavior.

Research Questions
For the purpose of this study, the following questions were posed to evaluate
primary care provider adherence with the NCEP ATP III guidelines for managing
dyslipidemia in the diabetic patient.
1. Are primary care providers achieving LDL-C levels < 100 mg/dL in accordance
with the NCEP ATP III guidelines for their diabetic patients?
2. a. Are primary care providers prescribing lipid-lowering medications as directed
by the NCEP ATP III guidelines?
b. If a lipid-lowering medication is prescribed, what agent is utilized?
c. If a lipid-lowering medication is not prescribed, is there a documented reason?
3. Are primary care providers documenting patient education on therapeutic lifestyle
changes?
4. Are primary care providers scheduling a follow-up appointment?
Definition of Terms
For purposes of this study, the following theoretical and operational definitions
are defined:
Type 2 diabetes mellitus
Theoretical: A chronic metabolic disorder marked by hyperglycemia. DM results
from either failure of the pancreas to produce insulin, which is type 1 DM, or from
insulin resistance with inadequate insulin secretion to sustain normal metabolism, which
is type 2 DM. Either type of DM can lead to microvascular and/or macrovascular
changes of the blood vessels. Type 2 DM is considered the adult onset and primarily
affects obese middle-aged individuals with sedentary lifestyles (Venes, 2009).
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Operational: Patients with an established diagnosis of elevated levels of glucose
in the body that requires medication treatment and have an ICD-9 code of type 2 diabetes.
The ICD-9 codes utilized began with 250.00 (the code for type 2 diabetes mellitus
without complications) but included all ICD-9 codes that began with 250.00, including
type 2 diabetes mellitus with complications.
Dyslipidemia
Theoretical: An abnormal amount of cholesterol in the blood (Free Dictionary,
2012).

Operational: Elevated LDL-C level'> 100 mg/dL and an ICD-9 code of
dyslipidemia (beginning with 272.00).
Low-density lipoprotein cholesterol (LDL-C)
Theoretical: A lipoprotein of blood plasma composed of a moderate proportion of
protein and a large proportion of cholesterol. LDL-C is the major atherogenic lipoprotein
and primary target lipid level when utilizing lipid-lowering medication (National
Cholesterol Education Program, 2002).
Operational: The cholesterol in the bloodstream that promotes plaque build-up
and increases risk of cardiovascular disease.
Lipid-lowering medication
Theoretical: Also known as hypolipidemic agents or antihyperlipidemic agents,
these drugs compose a diverse group of pharmaceuticals that are utilized in the treatment
of dyslipidemia (Free Dictionary, 2012).
Operational: Medication that decreases blood cholesterol levels.

5

Therapeutic lifestyle changes (TLC)

Theoretical. Changes to a patient's lifestyle that includes reduced intake of
saturated fat and cholesterol, therapeutic dietary options to enhance LDL lowering (plant
sterols/stanols and increased viscous fiber), weight control, and increased physical
activity (National Cholesterol Education Program, 2002).
Operational. Weight loss and/or change to low-fat diet and exercise.
NCEP ATP III Guidelines

Theoretical. A set of guidelines established by the National Institutes of Health
and the'National Cholesterol Education Program Adult Treatment Panel that serves as a
general outline and fundamental approach to lipid-lowering therapy. The guidelines
concentrate on the clinical approach to prevent coronary heart disease (CHD). The
guidelines also include the use of therapeutic lifestyle changes and statin therapy to lower
the CHD risk in patients with type 2 diabetes. LDL-C is upheld as the primary target for
lipid-lowering therapy within the guidelines (National Cholesterol Education Program,
2002).

Operational. Guidelines established to guide primary care providers in the
screening, treatment, and regulation of LDL-C levels in type 2 diabetic patients (see
Appendix A).
Primary care provider

Theoretical. An individual who helps in identifying, preventing, or treating illness
or disability (Free Dictionary. 2012).
Operational. Physician, nurse practitioner, or physician assistant who provides
medical care in the primary care clinics being surveyed.
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NCEP ATP III guidelines, and nearly 80% had levels above the optional goal of < 70
mg/dL. Adhering to these guidelines is imperative for utilizing evidence-based practice
to improve clinical outcomes in diabetic patients.
According to the Centers for Disease Control and Prevention (CDC) in 2011,
there were an estimated 25.8 million Americans (8.3% of the population) with diabetes
and another 57 million American adults with pre-diabetes. The prevalence of diabetes is
expected to double by the year 2050. Diabetes is the seventh leading cause of death in
the United States; diabetes costs have risen to $174 billion annually. The Study of
Economic Costs of Diabetes (2007) attributes $6,649 a year to diabetes cost per person,
with additional diabetes related costs at nearly twice that amount (.National Diabetes Fact
Sheet, 2011). As of 2004, 68% of diabetes-related deaths were caused by heart disease in
adults over the age of 65 (National Diabetes Fact Sheet, 2011).
Statement of Purpose
The purpose of this study was to evaluate primary care providers' adherence to
the NCEP ATP III guidelines in the treatment of type 2 diabetic patients. According to
the NCEP ATP III guidelines, it is imperative to achieve a LDL-C level < 100 mg/dL
(with an optional goal of < 70 mg/dL) in patients with type 2 diabetes so that the risks of
cardiovascular complications are minimized. The study reviewed the treatment
modalities utilized in patient care practices of each primary care provider. The use of
lipid-lowering drugs, as well as education concerning therapeutic lifestyle changes, was
reviewed. Based on the NCEP ATP III guidelines, the researchers determined whether
follow-up appointments were scheduled in accordance with the current guidelines.
This chapter detailed the significance and background of managing dyslipidemia
in diabetic patients. A lack of knowledge by the primary care provider regarding NCEP

ATP III guidelines increases the potential for cardiovascular complications in the diabetic
patient. The researchers examined the current practices of primary care providers in
south central Mississippi regarding their compliance to the NCEP ATP III guidelines.
According to the guidelines, therapeutic lifestyle changes and statin therapy are the
cornerstones of dyslipidemia management in diabetic patients. A crucial step in the
process is building a strong relationship between the patient and primary care provider.
In the following chapter, literature was reviewed to extract the current research findings
concerning dyslipidemia control in the diabetic population.

CHAPTER II
Review of Literature
In this chapter the researchers reviewed literature pertaining to the topic of
research. The articles reviewed are organized by distinct categories including
dyslipidemia to diabetic patients, medication options, the guidelines and adherence
thereof, and options for improvement. Literature relating to the conceptual framework
was also reviewed.
Conceptual Framework
Nola Pender's Health Promotion Model (HPM) has been widely utilized to aid in
nursing research worldwide. Pender, Murdaugh, and Parsons (cited in George, 2011)
stated that the HPM
. . . proposed a framework for integrating nursing and behavioral science
perspectives on factors influencing health behaviors. The framework offered a
guide for exploration of the complex biopsychosocial processes that motivate
individuals to engage in behaviors directed toward the enhancement of health, (p.
545)
The HPM is a versatile model that promotes research and supports nursing
practice. The model accounts for all aspects in nursing practice and views the patient
from a holistic perspective (George, 2011).
The HPM is based on several different personal factors, such as biological factors,
psychological factors, and sociocultural factors (George, 2011). Personal biological
factors include gender, age, pubertal status, body mass index, strength, balance, and
agility. Perceived health status, self-esteem, and self-motivation compose the category of
personal psychological factors. Lastly, personal sociocultural factors include race,
9
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ethnicity, acculturation, education, and socioeconomic status. The HPM also emphasizes
self-direction and self-efficacy. Self-direction, also known as self-regulation, is the
ability to direct and control one's thinking and actions (George, 2011). Self-efficacy can
be defined as one's own view of his or her personal ability to perform an identified set of
actions (George, 2011).
Nola Pender and Albeit Pender conducted a research study entitled Illness
Prevention and Health Promotion Services Provided by Nurse Practitioners: Predicting
Potential Consumers. The study was a cross-sectional survey of 388 residents who
explored the relationships between psychosocial and behavioral characteristics of the
population. The study also analyzed nurse practitioners' intentions to use illness
prevention and health promotion services (Pender & Pender, 1980). The survey revealed
that half of the United States' deaths were due to unhealthy behavior and improvements
in the health status of Americans can be made through illness prevention and health
promotion efforts (Pender & Pender, 1980). The purpose of the study was to determine
which subgroups within the population would most likely utilize health promotion
services provided by nurse practitioners (Pender & Pender, 1980). The outcomes of the
study indicated a high approval level of nurse practitioners, in the realm of health
promotion and disease prevention, even if the patient had an established physician
(Pender & Pender, 1980).
Kelley, Sherrod, and Smyth (2009) conducted a study on coronary artery disease
and smoking cessation intervention by primary care providers in a rural clinic. The studywas a nonexperimental, quality assurance retrospective chart review in a rural family
healthcare practice clinic located in the southern United States. Kelley et al. (2009)
reviewed the methods of primary care providers for evaluating smoking cessation in their

patients with a history of coronary artery disease for at least one year. Nola Pender's
Health Promotion Model was utilized in the study as the chosen framework, focusing on
the interpersonal influences pertaining to behaviors, beliefs, or attitudes of others. Kelley
et al. (2009) placed the primary care physicians in the role as the provider of
inteipersonal influence to aid in the cessation of smoking for their patients.
Murphey and Rew (2009) noted the need for nurses to educate pregnant minority
adolescents on the importance of oral hygiene. Murphey and Rew (2009) believed that
having optimal oral health was imperative for the health of pregnant adolescents and their
offspring's future well-being. Three different models were utilized to guide nursing
research and interventions related to oral health in pregnant minority adolescents, one
being Nola Pender's HPM. In conjunction with the HPM, Murphey and Rew (2009) used
the Influences on Oral Health and Oral Health Disparities Model (IOH-OHDM) and the
PRECEDE-PROCEED Model to guide their study. The HPM offered a process for
assessment of the patients' health-promoting behaviors. Murphey and Rew (2009)
believed that health promotion should be at the forefront of planning successful oral
healthcare interventions aimed at pregnant adolescents.
Phillips, Palmer, and Fenwick (2000) conducted a research study using Pender's
HPM as their framework to measure a person's attitude toward using a nurse practitioner
for their healthcare needs. The participants were classified by age, race, income level,
gender, and education level. Phillips et al. (2000) stated that, "Pender identified
cognitive-perceptual factors as primary motivational mechanism. Within this group is
perceived control of health, perceived self-efficacy, definition of health perceived health
status, perceived benefits of health-promoting behaviors and perceived barriers to healthpromoting behaviors" (p. 257). The researchers chose the HPM because it gave them the
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ability to effectively address individual, demographic, and societal influences toward
directing a patient's healthcare behaviors (Phillips et ah, 2000).
Pender's HPM provided an excellent framework for the research project entitled
Primary Care Management of Type 2 Diabetic Patients with Dyslipidemia according to
NCEP ATP III Guidelines. According to the HPM, the primary "purpose of health
promoting behavior is for the client to realize positive health outcomes such as improved
functional ability or improved quality of life" (George, 2011, p. 551). The current
research specifically explored the topic of dyslipidemia control which, if well controlled,
can positively impact the patient's quality of life. However, there are many different
factors that affect the efficacy of the applied treatments. Within the framework of
Pender's HPM, the current researchers also sought to identify any barriers that could limit
the end result of health-promoting behavior in the context of lipid management.
In the HPM several aspects of behavior-specific actions and cognitions that
contribute to health-promoting behavior were highlighted. However, each individual will
have a unique set of contributing actions and cognitions. These factors include perceived
self-efficacy, perceived barriers to action, perceived benefits of action, perceived
importance of health, perceived control of health, and definition of health (George, 2011).
An individualized approach is necessary when a healthcare provider is instructing a
patient on health-promoting behavior, according to Pender's HPM. Primarily, it is the
responsibility of the healthcare provider to encourage and educate health-promoting
behaviors. The NCEP ATP III guidelines supply healthcare providers with evidencebased interventions necessary for educating patients toward these health-promoting
behaviors.
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These interventions coincide with the behavior-specific cognitions of the HPM
theory. The NCEP ATP III guidelines suggest simplification of the medication regimen,
provision of clear and precise education to the patient, and follow-up times for
reinforcement of teaching. Utilizing these suggestions could help alter and improve the
patient's level of perceived self-efficacy. Another intervention the guidelines suggest
involved obtaining the support of family and friends to improve the patient's well-being
(National Cholesterol Education Program, 2002). This intervention can be categorized as
one of the "personal factors" of the HPM, where improvement is achieved through
interpersonal influences (George, 2011). By recruiting support from family and friends,
the practitioner promotes encouragement for health-promoting behaviors that the patient
will receive outside the clinic. But, according to Pender's HPM, the practitioner should
be included in the interpersonal relationships of the patient.
In addition to coinciding with behavior specific cognitions, the NCEP ATP III
guidelines also address perceived barriers of the HPM. Perceived barriers to action serve
as an important determinant of health-promoting behaviors (George, 2011). These
perceived barriers are defined as any barrier that directly blocks the positive goal or
indirectly blocks the commitment to work toward the goal. According to NCEP ATP III
guidelines, if a patient is having difficulty adhering to the treatment regimen, for any
reason, the practitioner should fill the role of encouragement (National Cholesterol
Education Program, 2002). Increasing the convenience and access to care could also
reduce this perceived barrier. The patient still needs to fulfill the health-promoting
behavior that is essential in maintaining adherence to the guidelines. By creating a sense
of ownership in the process, the patient will accept more responsibility. Encouragement
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is needed for the patient to adequately self-monitor, follow a diet and exercise plan,
and/or simply take the prescribed medications as instructed.
The NCEP ATP III guidelines also provide interventions focused on the primary
care provider to improve adherence. These interventions mostly include maintenance of
up-to-date education of the dyslipidemia disease process, reminders to attend to lipid
management on each individual patient, and development of a standard treatment plan
(National Cholesterol Education Program, 2002). As mentioned earlier, the practitioner
should be involved in the interpersonal influences model of the HPM for the patient. By
working as a team with the patient, the practitioner can influence the patient to maintain a
lifestyle that promotes healthy living and the practitioner can more closely adhere to the
NCEP ATP III guidelines.
Nola Pender's HPM has had a significant impact on past nursing research in the
United States and continues to remain relevant for current research in the United States
and abroad. The HPM is especially useful for the current research as it supports research
and is easily applied in a clinical setting. By encompassing the patient in a holistic
manner, the HPM incorporates a multitude of variables for providing the researcher with
a true assessment of the individual.
Review of Related Research
Dyslipidemia to diabetic patients. The role of various lipid measures in
determining risk of cardiovascular disease in diabetic patients continues to be a subject of
debate. In a study conducted by Tohidi et al. (2010), a population-based prospective
cohort study was performed comparing the effectiveness of different lipid components in
the prediction of cardiovascular disease (CVD). Middle Eastern diabetic and nondiabetic men and women, over the age of 30 years, composed the study group. These

Iranian participants were participants from a cross-sectional group out of the Tehran
Lipid and Glucose Study. Formulating the quantitative study, 1,021 diabetics and 5,310
non-diabetics were followed for a median of 8.6 years. These participants were required
to have no CVD at baseline (Tohidi et al., 2010).
The study was conducted using a pretested questionnaire with a trained
interviewer collecting important data, such as demographics, past and family medical
history, medication, and smoking usage. Waist-to-hip ratio (WHR), blood pressure
readings, and fasting cholesterol panels were obtained. Each participant received an
annual follow-up telephone call by a trained nurse to obtain information on any adverse
medical event experienced. Trained physicians collected complementary data pertaining
to the medical event, if occurred, during a home visit. Desired events included definite
myocardial infarction (MI), probable MI, unstable angina, angiographic proven coronary
heart disease (CHD), and stroke and/or death from CVD (Tohidi et al., 2010).
A Cox proportional hazard model was utilized to investigate the association of
lipid measurements with CVD outcomes. Final covariates included age, family history' of
premature CVD, intervention group, WHR, blood pressure, fasting plasma glucose,
smoking, aspirin use, antihypertensive and lipid-lowering drugs in men and women, and
menopause status in women. The Akaike Information Criterion (AIC) served to
determine the goodness of fit of the predictive models. A better model fit is indicated by
a lower value of AIC (Tohidi et al., 2010).
Over the course of the study, a total of 189 diabetics (men, n - 91; women, n 98) and 263 non-diabetics (men, n = 169: women, n = 94) experienced a type of desired
event. With multivariate analysis, only total cholesterol (TC)/high-density lipoprotein
cholesterol (HDL-C) was found to be significantly associated with a CVD desired event.

However, a one standard deviation increase in low-density lipoprotein cholesterol (LDLC) and non-HDL-C revealed an 18% increased risk of CVD. Interestingly, LDL-C,
according to Akaike Information Criterion, had the best fitness in multivariate models in
diabetic men. And again in diabetic women and non-diabetic men, the LDL-C
highlighted the best-fit multivariate model, followed by TC/HDL-C. Similarly in nondiabetic women, the LDL-C model was the 'most fit' model. A significant finding was
that only in non-diabetic men was there shown to be a marked protective effect from
increased HDL levels (Tohidi et al., 2010).
In both genders of diabetic and non-diabetics, high serum TC and LDL-C levels
were found to be risk factors for CVD. But, according to the Akaike Information
Criterion, the LDL-C model had superior risk prediction. When utilizing the
Framingham coronary risk score, the prediction accuracy remains the same when LDL-C
and TC are interchangeable. Tohidi et al. (2008) stated the following:
Our data according to important test performance characteristic provided evidence
based support for WHO recommendation that along with other CVD risk factors
serum TC vs. LDL-C, non-HDL-C and TC/HDL-C is a reasonable lipid measure
to predict incident CVD among diabetic men of a Middle Eastern cohort, (p. 8)
From this population-based study, results can be utilized to predict similar results
in other populations with high rates of diabetes. Strengths of the study included the 8.6year median follow-up time frame for incident CVD disease. The comprehensive lipid
panel allowed assessment of multifactoral components to demonstrate the contribution of
dyslipidemia in the causation of CVD disease in diabetic participants. Also, the inclusion
ot diabetics and non-diabetics afforded the study a comparison of rates of incident CVD
events over the course of the follow-up (Tohidi et al., 2010).
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Weaknesses of the study included the lack of repeat lipid measurements apart
from the initial blood draw. Secondly, no data were collected pertaining to the length of
time participants had been diagnosed with diabetes or their glycemic control, which can
play a major part in predicting CVD. Lastly, ApoA-1 and ApoB were not measured and
possibly should be considered in future studies due to the increasing interest in current
study results (Tohidi et al., 2010).
The study performed by Tohidi et al. (2010) is pertinent to the current study. By
affirming the current guidelines being utilized, the study gives this research greater
efficacy. As the current study focused on the LDL measurement in diabetic patients in a
primary care setting, it is important to validate the LDL component as being an adequate
predictor for CVD in diabetic patients
Tohidi et al. (2010) explained the importance of LDL in the cardiovascular
disease risks associated with diabetic patients. The following study explains that patients
with diabetes are at a high risk of developing cardiovascular disease associated with
dyslipidemia.
Lynch, Cooke, Rosen, Gandhi, and Bullano (2010) conducted a quantitative
cohort study comparing low-density lipoprotein cholesterol (LDL-C) goal attainment
rates in patients with differing access to lipid-modifying therapy. The purpose of the
study was to identify barriers in a primary care setting that prohibited achievement of
LDL-C goals according to current guidelines. Once these barriers were identified, they
could then be applied toward creating quality improvement initiatives (Lynch et al.,
2010).
The setting for the study was a primary care facility in Connecticut, USA. A total
of 5,936 participants were chosen from a managed care organization (MCO) and

categorized into risk stratification according to their coronary heart disease (CHD) risk as
established by the NCEP ATP III guidelines. The risk stratification categories included
low, moderate, high, and very high. The participants were also categorized into four
different lipid-modifying therapy groups: restricted, unrestricted, other, and no lipidmodifying therapy. As defined by the MCO, restricted therapy included atorvastatin,
rosuvastatin, and simvastatin/ezetimibe fixed-dose combination. Unrestricted therapy
included fluvastatin, lovastatin, pravastatin, and simvastatin monotherapy. A steptherapy program of the MCO required patients to begin with an unrestricted medication
for a minimum of a 90-day trial before becoming eligible, based on LDL-C results, for'a
restricted medication. The other category included any other alternative lipid-modifying
combination statin therapy or nonstatin lipid-modifying therapy. And lastly, the "no
lipid-modifying therapy" group was any participant not prescribed a lipid-modifying
therapy (Lynch et al., 2010).
Participants were required to be 18 years or older, insured by the regional MCO,
and have one baseline LDL-C measurement at the study site facility in the year of
initiation of the study (2007). Data were collected from the MCO and primary care
practice databases, including demographic data, laboratory data, diagnosis codes, and
pharmacy claims. The identities of participants were kept confidential in accordance
with the Health Insurance Portability and Accountability Act (Lynch et al., 2010).
For CHD risk, the very high-risk category included participants with a history of a
CHD event, as well as a diagnosis of diabetes, metabolic syndrome, and/or intermediate
coronary syndrome. The high-risk category included ICD-9-CM codes for myocardial
infarction, other ischemic heart disease, angina pectoris, symptomatic carotid artery
disease, peripheral arterial disease, abdominal aortic aneurysm, or diabetes mellitus
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diagnosis. The moderate-risk category included participants with two or more risk
factors, that included age (men > 45 years old and women >55 years old), high-density
lipoprotein cholesterol < 40, and hypertension diagnosis/antihypertensive therapy. Lowrisk included participants with less than one risk factor (Lynch et al., 2010).
The primary endpoint measured in the study performed by Lynch et al. (2010)
was the percentage of patients achieving LDL-C goals. Each risk category had a
different LDL-C goal according to the NCEP ATP III guidelines. LDL-C goals were
defined as < 160 mg/dL for the low CHD risk category, < 130 mg/dL for the moderate
CHD risk category, < 100 mg/dL for the high CHD risk category, and < 70 mg/dL for the
very high CHD risk category. LDL-C goal rate attainment statistics were obtained and
compared using chi-square tests. Logistic regression analysis was utilized to evaluate the
influence of demographic and clinical factors on the attainment goal of LDL-C. The
study set the statistical significance at an accepted alpha (p < .05) (Lynch et al., 2010).
From the total 5,936 participants, 58.6% were classified as low CHD risk, 24.6%
were classified as moderate CHD risk, 14.9% were classified as high CHD risk, and 1.9%
were classified as very high CHD risk. Out of the entire cohort, 12.2% of participants
were diabetics. The total number of participants that met their LDL-C goal levels was
4,638 (78.1%), but overall goal attainment rates were significantly lower in the high and
very high CHD risk categories. For the high-risk CHD category, goal rates were found to
be 52.6%, and for the very-high risk CHD category goal rates revealed a low of 31.6%.
A direct inverse correlation existed between CHD risk and percentage of participants that
reached their LDL-C goal as the CHD risk increased the rate of goal attainment
decreased. However, a positive correlation relationship existed between the rate of goal
attainment and degree of drug progression (no therapy, other therapy, unrestricted
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therapy, restricted therapy) on a continuum. In the multivariable logistic regression
model, factors that were associated with improving rates of goal attainment included
increasing age, male, and use of restricted lipid-modifying therapy (Lynch et ah, 2010).
Limitations of Lynch et al. (2010) were recognized as having considerable impact
on results. One such limitation is lack of more extensive data points. Smoking status,
family history of CHD, and blood pressure measurements, if supplied, would have
allowed a more accurate calculation for risk stratification category. Another important
limitation to note was the omission of medication adherence. This factor could have
greatly affected study results for meeting LDL-C goal levels, specifically if there was a
difference in participants' medication adherence in one lipid-modifying therapy group
over another group (Lynch et ah, 2010).
Lynch et al. (2010) is pertinent to the current research study. The current research
focused on the diabetic population, which falls into the high or very high CHD risk
stratification. The Lynch et al. (2010) study revealed data that clearly raises alarm to the
percentage of these two categories failing to reach the target goal for LDL-C level.
According to the study results, approximately half of the high-risk and two thirds of the
very high-risk category did not achieve goal LDL-C levels. This finding is alarming due
to the fact that these two categories represent the most likely group to suffer adverse
cardiovascular events, adding increased costs and healthcare burden. Lynch et al. (2010)
acknowledged that national guidelines have stressed aggressive management for this
high-risk population and "yet current practice yields suboptimal results" (p. 345). In
addition, two contributing factors affecting the failure to reach the LDL-C goal are lack
of titration of drug therapy by the healthcare provider and the greater percentage of LDL-
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C reduction necessary to meet the goal level in high- and very-high risk categories
(Lynch et al., 2010).
Medication options. Hyperlipidemia in individuals with diabetes places them at
an increased risk for cardiovascular disease. Diabetes is the seventh leading cause of
death for Americans: and, with an added diagnosis of hyperlipidemia, their chance of
death only increases (National Institute of Diabetes and Digestive and Kidney Diseases,
2011). Dyslipidemia is the main component of the insulin resistant syndrome and type 2
diabetes. A group of medications called statins can help lower lipid levels to a
therapeutic range for those with diabetes and help decrease their risk of cardiovascular
disease. Eliasson et al.'s study (2011) compared the lipid-lowering effect of different
statin medications patients with type 1 and type 2 diabetes. The purpose of this
observational study was to describe the use and compare the ability of different statin
medications in lowering LDL-C levels. Eliasson et al. quoted the American Diabetes
Association's Standard of Medical Care in Diabetes by stating that, "in order to reduce
cardiovascular risk, the US guidelines promote statin use in patients with diabetes"
(Eliasson et al., 2011, p. 9).
The study was conducted using informational data from the Swedish National
Diabetes Register (NDR) and linking it through personal identification numbers with data
from two other registers, the Prescribed Drug Register and the Swedish Patient register
( Eliasson et al., 2011). The sample consisted of patients listed in the National Diabetes
Register between the ages of 18 and 75 years with a diagnosis of diabetes for more than
one year. The patients also could not purchase any lipid-lowering medications one year
prior to the start of the study. Inclusion criteria also consisted of filling at least three
prescriptions during the one-year study timeframe, which ensured that the participants
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were on the medications for about the same time span. The researchers used linear
modeling to compare clinical characteristics such as age, sex, length of diabetes
diagnosis, body mass index, blood pressure, HbAic, smoking and reduction in cholesterol
level. They included a 'missing value' of LDL-C as a single category of their main
analyses to avoid a large reduction of the number of eligible participants. The University
of Gothenburg approved the study and all patients agreed to be reported. Information for
this study was pulled from a period of time over 3 years when configuring the start time
of patients who could not have been prescribed a statin medication.
Results from the study were presented by pairing each statin with the effects on
LDL-C levels. The medications listed were simvastatin, pravastatin, fluvastatin,
atorvastatin, rosuvastatin, ezetimib, fibrate, statin with a fibrate, and statin with an
exetimib. Results indicated that diabetic patients who were prescribed simvastatin,
atorvastatin, or rosuvastatin had lower lipid levels and that all three medications had close
to the same results when compared to each other. When a statin was used with a fibrate
or ezetimib, it would lower the LDL-C level as well. Diabetic patients who were
prescribed pravastatin, fluvastatin, ezetimib, and fibrate alone to treat their
hyperlipidemia seldomly reached therapeutic LDL-C levels (Eliasson et al., 2011). The
study indicated that the statin medications were prescribed in low doses and higher doses
should have been prescribed when the recommended LDL-C level was not reached.
Their research showed 75% of patients with type 1 diabetes were treated with simvastatin
or atorvastatin. Within those 75% of patients, their LDL-C levels were very close in
range and the research showed their cardiovascular disease history was less common.
When comparing the LDL-C levels before treatment and after treatment, the most
noticeable LDL-C lowering lipid level medications were seen in diabetic patients who

23
were started on simvastatin, rosuvastin, ezetimid, or statin plus ezetimib combination.
Diabetic patients who were put on pravastatin and fluvastatin did not have a dramatically
lower lipid level when compared to their initial lipid level.
When gathering information for the current research study, the researchers
recorded the medications patients were prescribed after therapeutic lifestyle changes were
unable to lower their LDL-C level. The information provided in this study can be used as
a comparative guide to see if current healthcare providers are choosing proper statin
medications based on patient's history and any other co-morbidities. The data collected
in this study indicated which medications are not effective in lowering lipid levels in
diabetics. This study showed that simvastatin was the first drug of choice since 2003 for
lowering lipid levels (Eliasson et al., 2011). Only a few patient characteristics were
different from those who were prescribed simvastatin, atorvastatin, or rosuvastatin.
Individuals who were placed on atorvastatin and rosuvastatin had a greater history of
renal disease or cardiovascular disease. It is likely that the patient's history and co
morbidities were the basis for the choice of statin medication (Eliasson et al., 2011).
However, a significant finding in this study was the prescription medication dosing. The
prescribers used low dose amounts on their patients; by the end of the study some of the
patients had not reached a therapeutic LDL-C level. The patients in this study were
selected by the completeness of the analyzed data, suggesting that they are indeed
representative (Eliasson et al., 2011). With that being said, there might be slight errors in
the clinical characteristics and additional risk factors values from clinics where these are
reported manually instead of automatically from computerized medical records systems.
Eliasson et al. (2011) is relevant to the current study due to the evaluation of lipidlowering levels by using different forms of statin medications. The current study
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evaluated the control of LDL-C levels in patients who have diabetes according to the
National Cholesterol Education Adult Treatment Panel. Statin medications have been
proven to lower cholesterol levels, and this study showed they work effectively in
diabetics. When cholesterol levels are lowered, the risk of having a cardiovascular
complication is decreased dramatically. The information provided in this study was used
as a comparison guide to see if the results to specific medications are still the same as the
current researchers' more recent study results. The framework was not mentioned in
Eliasson et al. (2011).
The conclusion from Eliasson et al. (2011) is that simvastatin is the drug of choice
for dyslipidemia in patients with diabetes. The following research findings revealed that
using a statin medication in combination with another form of cholesterol lowering
medication might be more effective.
Simvastatin has been shown in research as the medication of choice when treating
a diabetic for hyperlipidemia. However, in some patients, a statin medication alone is not
strong enough to maintain a therapeutic LDL-C level according to the ATP III guidelines.
Toth, Zarotsky, Sullivan, and Laitinen (2009) conducted a retrospective database analysis
evaluating a statin-fibrate combination drug therapy to better control lipid levels and
decrease the cardiovascular risk in diabetic dyslipidemia patients. According to Toth et
al. (2009), cardiovascular disease is the primary cause of morbidity and mortality in
patients with type 2 diabetes despite the availability of effective therapies to treat major
risk factors, such as elevated cholesterol levels. Even a slight elevation in LDL-C levels
in diabetic patients puts them at a much higher risk for a cardiovascular attack. The
escalating rate of insulin resistance is coinciding with the increased incidence of mixed
dyslipidemia (Toth et al., 2009).
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The retrospective study was conducted within the U.S. The research team used
pharmacy and medical data along with laboratory results and enrollment infonnation
from a large U.S. healthcare plan. The majority of the study participants were from the
southwestern part of the United States. The patients' age, sex, and geographic locations
were attained from the enrollment data and their LDL-C, HDL-C and TG levels were
attained from the lab results data. The analysis monitored patients 182 days prior to the
index date and 182 days after the index date (Toth et al., 2009). The patients' LDL-C,
HDL-C and TG lab levels were all drawn on the same day and same time during a time
period of January 1, 2006, through December 31, 2006 (Toth et al., 2009). From within
that time period, an index date was established. The index date was decided upon the
first suboptimal or the first optimal lab result. From that point in the analysis, two groups
were formed. The first group consisted of participants with their LDL-C, HDL-C, and
TG in a therapeutic range. This group was called the optimal cohort. The second group,
called the suboptimal cohort, had at least one lipid level below the optimal goal. For
diabetic patients, suboptimal lipid values were classified as LDL-C > 100 mg/dL, HDLC < 40 mg/dL for men and < 50 for women and TG >150 mg/dL (Toth et al., 2009). The
goal of this study was to determine lipid treatment patterns in diabetic patients with
mixed dyslipidemia (Toth et al., 2009). All data collected for this study were assessed
with protocols compliant with the Health Insurance Portability and Accountability Act
(Toth et al., 2009).
The LDL-C goal category was divided into four risk categories: (a) age/gender
(male > 45 years; female 2: 55 years), (b) cardiovascular heart disease (a medical claim
indicating presence of CHD during the pre-index period), (c) hypertension (presence of
ICD-9 CM code 401.x-404.x, 642.0x-642.7x during the pre-index period), and (d)
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diabetes (presence of ICD-9 code 250.xx or at least two filled prescriptions for oral
antidiabetic agents during the pre-index period) (Toth et al., 2009). The existence of any
pharmacy claim for any lipid treatment was defined. This study determined which
prescription treatment the patient was on pre- and post-index period from the following
groupings: (a) pharmacy claim for a statin and without a claim for other lipid-modifying
medications, (b) pharmacy claim for a fibrate without a claim for other lipid-modifying
medications, (c) pharmacy claim for a niacin/nicotinic acid and without a claim for other
lipid-modifying medications, (d) pharmacy claim for "other" medication and without a
claim for other lipid-modifying medications, (e) pharmacy claim for a statin and a fibrate,
(f) pharmacy claim for a statin and niacin/nicotinic acid, (g) pharmacy claim for a statin
and other lipid-modifying medication, (h) pharmacy claim for a fibrate and a niacin; 9:
pharmacy claim for a fibrate and other medications, (i) pharmacy claim for a niacin and
other medications, (j) combinations other than those already mentioned, and (k) no claim
for a lipid-modifying medications (Toth et al., 2009). All data were evaluated
descriptively. Values and percentages were provided for dichotomous and
polychotomous variables (Toth et al., 2009). Means, medians, standard deviations, and
percentiles are provided for continuous variables. Differences in mean values were
assessed using a t test and differences in proportions were assessed using a chi-square test
(Toth et al., 2009).
Results from the analysis showed that in the pre-index phase, 68% of diabetic
participants had elevated LDL-C and HDL-C levels and 58% percent of diabetic patients
had elevated LDL-C and TG levels. Neither of the two participant samples was receiving
medication treatment for their dyslipidemia at that time. When compared to the postindex phase, the percentage of diabetic patients with elevated LDL-C and HDL-C levels
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not receiving lipid-lowering therapy dropped 10%. The percentage of diabetic patients
with suboptimal LDL-C and TG levels not currently on lipid therapy dropped 15%. For
the patients who were treated with statin therapy, 25%-37% were started on a statin
monotherapy, 3%-6% received a fibrate alone, and > 1% was prescribed monotherapy
niacin during the post-index period (Toth et ah, 2009). When comparing the pre-index to
the post-index, the percentage of patients who were prescribed a statin combination
medication therapy remained subpar. From the participant sample, 32,855 diabetic
patients had an elevated LDL-C level in the pre-index phase and were not on any lipidlowering medication (Toth et al., 2009). Of the same participants in the post-index phase,
a high percentage was not on any lipid-lowering therapy. Very few had been prescribed
lipid-lowering medications. Of all three lipid levels, whether if one, two or three were
elevated, the most common'treatment was a single statin monotherapy drug. Over 42%
of diabetic patients with mixed dyslipidemia received no lipid-modifying therapy after
suboptimal lipid levels were attained, and the ones who would have benefited from a
combination drug were prescribed a single statin medication (Toth et al., 2009).
There were a few weaknesses found in the study. The limitations in this study
were the prescription claims. They provided no true indication if the medication was
taken as prescribed, and it did not identify those patients who might have received
medication samples or who may have filled their medications outside the pharmacy
organization. Another limitation was not clarifying when the blood was obtained for lab
testing or if the patient was instructed to fast (Toth et al., 2009). Lastly, a weakness was
presented when the data claims were gathered for the purpose of compensation instead of
research. Due to this flaw, the patient's medical history may not have been accurately
obtained.
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The findings of this research indicated that providers are not adequately treating
hyperlipidemia in diabetic patients. This study revealed that a statin plus a fibrate will
help in lowering lipid levels in diabetics when a single statin medication is not lowering
the patient's lipid level to a therapeutic range. Diabetics have an increased mortality rate;
when hyperlipidemia persists in a diabetic, the risk of cardiovascular complications and
death increases.
This study's findings are congruent with the current research topic in providing
evidence that providers can achieve optimal LDL-C levels in their diabetic patients along
with controlling their HDL-C levels and TG levels. Despite the availability of treatment
guidelines for dyslipidemia management and a wealth of research defining the benefits of
lipid-modifying therapy to reduce the risk of cardiovascular health disease in diabetic
patients, research continues to support the fact that diabetic patients are consistently
maintaining elevated lipid levels (Toth et al., 2009). The results of this analysis propose
that diabetic patients are not being treated to reach the ADA-suggested target lipid levels.
No framework was mentioned throughout the analysis.
To increase the effectiveness of the statin medication, the following research
study also used a different form of cholesterol-lowering medication in combination with
the statin. Controlling dyslipidemia in type 2 diabetic patients is pertinent in reducing
their mortality rate. By regulating multiple risk factors, such as hypertension,
dyslipidemia, and hyperglycemia to a therapeutic level, providers can greatly lower the
risk of a type 2 diabetic patient having a cardiovascular attack or developing heart
disease. A patient with diabetes is at an increased risk of nephropathy, retinopathy, and
many other health complications. Elevated cholesterol levels increase the risk of death
and other serious health concerns, especially in the presence of diabetes. Colesevelam
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can help lower LDL-C and non HDL-C levels in diabetics along with lowering their
glucose levels. It can be used alone or in combination with other statin medications, such
as simvastatin, to help aid in lowering cholesterol levels (Fonseca, Handelsman, & Staels,

2010).
Colesevelam is a bile acid sequestrant and in this trial review, it was proven to
help lower glucose and cholesterol levels. The study conducted by Fonseca et al.
reviewed a three-phase randomized, double-blinded clinical trial that monitored the
ability7 of colesevelam to lower glucose and lipid levels when added to other antidiabetic
medication treatments for'clients with type 2 diabetes. Colesevelam was compared to a
placebo in a monotherapy trial and a combination therapy trial over a 26-week period.
The study enrolled 1,064 participants with a known diagnosis of type 2 diabetes that had
uncontrolled glucose levels while on their current diabetic medication regimen. The
mean age of participants was 56 years old. Participants were all men, and either from
Caucasian. Latino, or African American descent. Baseline HbAic levels were similar
across the three trials ranging from 8.1% to 8.3%. LDL-C levels ranged from 99.0mg/dL
to 106.0mg/dL in the beginning of the study. Compliance among participants ranged
from 92.7-93.3% with the medication colesevelam and 90.8-94.5% with placebo
(Fonseca et al., 2010).
The first trial was supplementing colesevelam with metformin. With the addition
of colesevelam to metformin, HbA,0 levels were reduced at week 6 and week 26 lab
draws. The average decrease in HbA!c was -0.54%. When compared to the participants
who used the placebo, colesevelam substantially lowered the fasting glucose level. A
-ub"roup analysis was conducted to evaluate colesevelam"s ability to reduce HbAic in
metformin monotherapy and metformin combination therapy with other antidiabetic
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medications. The results showed colesevelam lowered HbAic levels in both subgroups,
-0.47% and -0.62%, respectively. When studying the lipid levels after colesevelam was
added to metformin, the lipid levels were reduced. LDL-C was reduced approximately
16% at week 26. The combination therapy reduced total cholesterol levels and non HDLC levels. The NCEP ATP III suggested non-HDL-C levels are < 130mg/dL to reduce
CVD in type 2 diabetics, with an optimal goal of < lOOmg/dL. HDL-C levels increased
from baseline with the combination drug therapy (Fonseca et al., 2010).
Trial two consisted of adding colesevelam to a sulfonylurea-base therapy. Two
subgroups were established, one group receiving colesevelam and the other group
receiving a placebo. By adding colesevelam to sulfonylurea monotherapy, HbAic levels
dropped -0.79%; when added to a sulfonylurea combination therapy, levels reduced
-0.42%. Colesevelam also reduced the fasting plasma glucose levels. Colesevelam
lowered HbAicand fasting plasma glucose levels 47.5% compared to a 32.1% reduction
from placebo use. Levels were drawn at the 26th week of therapy. Lipid levels were
attained during this trial and when adding colesevelam to a sulfonylurea regimen. Total
cholesterol, LDL-C, and non-HDL-C levels were considerably lower by week 26. Total
cholesterol was reduced -5.0, LDL-C had a mean reduction at -16.7%, and non-HDL-C
levels lowered -6.7%. HDL-C did increase with this treatment; however, the increase
was minimal (Fonseca et al., 2010).
Trial three reviewed the glucose and lipid levels associated with adding
colesevelam to insulin based therapy. The trial reviewed insulin alone treatment and
reviewed patients who used insulin plus another form of oral antidiabetic. Four weeks
after starting colesevelam, HbA]c levels began to drop in both subgroups. They were
significantly lower by 16 weeks with a mean difference of-0.50%. In both subgroups,
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colesevelam lowered HbAjG levels by -0.59% and -0.44%. Fasting plasma glucose was
also reduced but not significantly. Colesevelam lowered HDL-C, non HDL-C, and total
cholesterol by week 16; however, the decrease in the levels was not much different from
the placebo effects. LDL-C levels were substantially reduced by -12.8 when colesevelam
was added to insulin therapy (Fonseca et al., 2010).
In all three trials, colesevelam was proven to lower the risk of cardiovascular
attacks in type 2 diabetics. Across the board, HbAic levels were reduced in antidiabetic
monotherapy and combination therapy. LDL-C and non-HDL-C levels were reduced in
all trials and in all categories of the study. In diabetic patients with triglyceride levels
above > 300mg/dL, caution was needed from the primary care provider because the
triglyceride levels were increased in the study trials. Colesevelam in not recommended
for diabetic patients who have a triglyceride level > 500md/dl. Colesevelam was
tolerated well by all participants who were prescribed the medication. Hypoglycemia is
always a risk when adding a medication to a type 2 diabetic patient. The study took into
account this risk and monitored for any hypoglycemic episodes. Colesevelam minimally
increased the risk of hypoglycemia. Twelve participants had a hypoglycemia episode,
they were considered mild, and treatment was not stopped (Fonseca et ah, 2010).
This trial study was relative to the current research project in helping determine
how primary healthcare providers can achieve therapeutic LDL-C and glucose levels with
combination cholesterol and diabetic medications. This study provided three different
trials comparing how colesevelam works in lowering glucose and lipid levels in diabetic
patients v/ho are on an insulin or oral form of anti-diabetic medication. The use of
colesevelam reduced the risk of cardiovascular risk in diabetic patients by lowering non-
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HDL-C, HbAic, and LDL-C levels. Limitations to this study were the participants were
all men. No theoretical framework was provided (Fonseca et al., 2010).
The previous three literature reviews demonstrated that the use of statin
medications, alone or in combination with other lipid-lowering medications, is sufficient
in treating dyslipidemia in diabetic patients. The following literature review discusses
the use of lifestyle changes to treat dyslipidemia, as compared to the use of statin
medication.
The current NCEP ATP III guidelines advocate aggressive multifactorial risk
factor intervention for diabetics and delineate two different treatment groups for the
primary prevention of dyslipidemia, including statin therapy and therapeutic lifestyle
changes (National Cholesterol Education Program, 2002). Becker et al. (2008) conducted
a quantitative single-center, randomized trial comparing the iipid-lowering effects of
standardized statin therapy with an alternative regimen of therapeutic lifestyle changes
(TLC), fish oil, and red yeast rice (RYR). The primary purpose of the study was to
discover whether TLC, fish oil, and RYR effectively lowered low-density lipoprotein
cholesterol (LDL-C) as compared to those patients receiving statin therapy in a primary
prevention population.
A total of 74 patients from a cardiology practice in suburban Philadelphia,
Pennsylvania, were selected to take part in the study. Approval for the trial was obtained
from the Institutional Review Board of Chestnut Hill Healthcare. The participants, aged
18 to 80 years, met the hypercholesterolemia requirements based on the NCEP ATP III
guidelines. To be included in the study, participants needed a baseline LDL-C > 130
mg/dL and two or more cardiovascular risk factors or a baseline LDL-C between 160-210
mg/dL and zero or one cardiovascular risk factor. Cardiovascular risk factors included
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diabetes mellitus, hypertension requiring treatment, HDL-C < 40 mg/dL, current cigarette
smoking, family history of premature coronary artery disease, and men > 45 years or
women >55 years or postmenopausal. The exclusion criteria included known coronary
artery disease, baseline triglyceride levels > 400 mg/dL, warfarin use, severe kidney or
liver disease, systemic disease, or an orthopedic condition that would not allow for
aerobic exercise. Written informed consent was obtained from those participants who
qualified for the study based on the inclusion and exclusion criteria (Becker et al, 2008).
A computer-generated simple randomization list was utilized to allocate
participants to the simvastatin group or alternative treatment group (AG). The
simvastatin group received 40 mg/dL of a 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitor (statin) as well as traditional counseling on diet and exercise. The
counseling for the simvastatin group was performed using a preprinted handout from the
American Heart Association recommendations. The AG group received a
multidisciplinary lifestyle program with weekly meetings taught by board-certified
cardiologists, exercise physiologists, dieticians, and alternative relaxation practitioners.
Teachings encouraged a Mediterranean style diet, aerobic exercise five to six times per
week, and relaxation techniques, such as yoga. In addition, the AG group received fish
oil and RYR supplements (Becker et al., 2008).
The study was conducted between April and June 2006, and results were
quantified at the end of the 12-week period. The primary end-point was the percentage
change of LDL-C from baseline levels. Secondary end-points included changes in other
lipoproteins and weight loss. Analyses were performed using SAS software. Multiple
linear regressions were used with the treatment group, including an adjustment for
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baseline weight; p < .05 was considered statistically significant; and all tests were twosided (Becker et al., 2008).
In both the simvastatin and AG group, there was a statistically significant
reduction in LDL-C levels from baseline; no significant difference was noted between
each group. Although results in the AG group demonstrated an LDL-C reduction of 3.1
mg/dL greater than in the simvastatin group, it was not statistically significant. However,
in the AG group there was a significant reduction in triglycerides when compared to the
simvastatin group of-36.4 mg/dL. Another secondary end-point measured was weight;
the AG group had a superior weight loss to the simvastatin group (Becker et ah, 2008).
Strengths of the trial included the randomization of participants, excellent
adherence of participants, no loss of participants for the remainder of the study time, and
the yielding of statistically significant changes in outcome measurements (serum LDL-C
levels and weight loss). Limitations of the trial included being a single site, unblinded
study, of limited scope, and brief course of 12 weeks. In the future, a larger and multicentered trial with prolonged follow-up would be useful in further investigating the
comparison of treatment options in dyslipidemia (Becker et al., 2008).
The study performed by Becker et al. (2008) was pertinent to the current study of
dyslipidemia in diabetic patients. As shown in the study results, advantages of TLC were
reflected in the AG group as having superior triglyceride reduction and increased weight
loss when compared to the statin group. These were two vitally important end-points for
diabetic patients with dyslipidemia in decreasing risk of cardiovascular disease. TLC in
the current guidelines includes reduction of saturated fats and cholesterol, therapeutic
dietary options to enhance LDL lowering, weight control, and increased physical activity
(National Cholesterol Education Program, 2002). The results of Becker et al. (2008)
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confirms that TLC and statin therapy are appropriate and effective therapies as suggested
in NCEP ATP III guidelines, which were the basis of the current study. Whether primary
care providers prescribe statins, teach TLC, or combine therapies, it is important to know
the efficacy of each modality in current research.
The guidelines and adherence thereof. A group of researchers put together a
multinational survey referred to as The Lipid Treatment Assessment Project. This project
was to be used for assessing how well physicians were adhering to the NCEP ATP III
guidelines for management of total cholesterol of their patients. Patients were placed in
low-risk, moderate-risk and high-risk categories to assess the control over each group.
Low-risk patients were those considered to have > 1 risk factor. Moderate risk patients
were those considered to have > 2 risk factors. High-risk patients were those with
existing coronary or atherosclerotic disease or diabetes mellitus. The project showed that
out of 4,888 patients being treated in the United States, 38% achieved the goal of low density lipoprotein cholesterol (LDL-C) level from 1996 through 1997.
To reevaluate the current compliance and efficiency of treatment, a second survey
was completed. The Lipid Assessment Project 2 was performed using over 10,000
patients from nine countries. There were 3,000 patients were from the United States,
which made up the largest portion of the study. There were 1,000 patients from Canada,
Spain, Netherlands, France, Taiwan, and Korea. They chose 400 patients from Brazil and
600 patients from Mexico. The survey was administered from September 2006 through
April 2007. Each part of the study was approved through an institutional review board
(IRB), and each patient had to sign a written informed consent stating that information
could be used and published. Throughout the study, no identifiable information was
published. The guidelines used for the United States were the NCEP ATP III.
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Eligibility to be included in the study was age > 20 years and evidenced of being
treated with the same lipid-lowering therapy for 3 months. Diet and exercise were
included as lipid-lowering therapy as well. The average age was 62 years with a standard
deviation of ± 12 years, and 54% of the patients were male. Medical history was
reviewed for each patient, and data were gathered on smoking, alcohol use, and familial
history of coronary or atherosclerotic disease, hypertension, hypothyroidism, nephrotic
syndrome, liver disease, and diabetes mellitus. The current cholesterol-lowering
medications used by each patient were documented in the study.
The most common statins used for treatment to lower LDL-C were atorvastatin,
simvastatin, rosuvastatin, and pravastatin. Seventy-five percent of the patients were on
statin mono-therapy. In the second study, 31% of the patients were diabetics. Eight
hours of fasting was required prior to lab work for each patient, and samples were
analyzed by the same laboratory. Lab work included total cholesterol, HDL-C,
triglycerides, blood glucose, and C-reactive protein using high sensitivity analysis.
Results of the second study showed a vast improvement over the first study in
regard to lipid control but at the same time showed a need for improvement. The results
were broken down within each risk factor group. The overall success rate was 73% of all
three groups. In the low-risk patients, 86% reached the goal with a mean LDL-C level of
108 (± 27) mg/dL. The moderate risk group had 74% goal achievement with a mean
LDL-C level of 92 (± 22) mg/dL. The high-risk group had a total of 67% of goal
achievement with a mean LDL-C level of 7J (± 17) mg/dL.
These numbers are quite an improvement from the first study which showed a
38% overall achievement with an 18% achievement in high-risk patients. This still
leaves one third of the high-risk group needing improvement in lipid-lowering therapy.
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These patients need to be continually monitored and receive aggressive therapy to
decrease their risk of morbidity and mortality. The major limitation of the study was that
it only represents the efficiency of the physicians involved within the study.
The current research study is useful to the current research because it provides
statistical verification of how well primary healthcare providers are following the
guidelines provided to control cholesterol in all risk groups of patients. The data pointed
to an increased need to continue improving on management of high-risk patients. This
study indicated the use of statin medications being the number one choice of medication
because of the high rate of successful goal achievement. The study also reflects the
importance of continuing research into primary care providers' treatment of patients with
dyslipidemia.
The previous literature review discusses how well primary care providers are
doing in adhering to the guidelines and the importance of these guidelines. The
following review is based on a survey comparing primary care providers' adherence to
the guidelines on a much larger scale than the previous one.
The Stop Atherosclerosis in Native Diabetic Study (SANDS) was conducted to
compare the difference of reaching the standard targets for two groups with a low-density
lipoprotein cholesterol (LDL-C) of < lOOmg/dL with a systolic blood pressure (SBP) of
< 130mm/Hg and a group with a LDL-C of < 70mg/dL or lower with a SBP of
< 115mm/Hg (Howard et al.. 2008). The goals for LDL-C levels were attained from the
NCEP ATP III guidelines. The goals for the SBP were taken from the Sixth Joint
National Committee on Prevention, Detection, Evaluation, and Treatment.
This study was conducted from 2003 through 2007 in four different clinical
centers in Arizona, Oklahoma, and South Dakota. The population chosen for the study
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was American Indian men and women ages 40 years and greater who were diagnosed
with diabetes mellitus type 2 and had no prior cardiovascular events. Once chosen for the
study, each participant had to sign written consent.
There were a total of 548 participants that were placed randomly into an
aggressive or standard group (Howard et al., 2008). The aggressive group had goals set
to achieve an LDL-C level of < 70 mg/dL and an SBP <115 mm/Hg while the standard
group had an LDL-C goal of < 100 mg/dL and an SBP of < 130 mm/Hg. Their primary
care providers who were part of the study throughout the trial monitored the participants.
The primary care providers handled all other medical conditions along with assessing
their DM and therapeutic lifestyle change education. To prevent the primary care
providers from adjusting medications dealing with the lipid levels and blood pressure,
targets were placed in the medical records of each participant to be seen by each provider.
Each group had the same algorithm followed by the physicians for treatment of their
blood pressure and lipid levels. The initial visit included a physical examination,
electrocardiogram, carotid artery ultrasound, echocardiogram, collection of demographic
data, health history, and current medication use. Each participant had an initial height,
weight, waist circumference, seated blood pressure, and fasting lab work. If the lifestyle
changes were not successful, the use of statin drugs was initiated. If the goals were not
achieved at this point, they were placed on a combination therapy with ezetimibe. The
changes were made at physicians' discretion based on the participants' health and
medication history. Each group had a follow-up visit after one month from initial visit
and then every 3 months for the duration of the study.
The researchers were trying to determine if achieving the lower targets for LDL-C
levels and SBP would slow the progression of atherosclerosis, which would lead to a
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decrease in cardiovascular events in diabetic patients. The results suggested maintaining
lower targets for LDL-C and blood pressure would decrease atherosclerosis and left
ventricular hypertrophy when compared with maintaining the standard goals.
One of the limitations of the study was that it only used one ethnic population and
it was a small sample. It would be helpful to increase the number of patients in the study
along with different ethnic backgrounds. The researchers discussed the need to continue
this research to ensure that the long-term benefits of achieving the more aggressive goals
would be beneficial not only in decreasing CVD events but also economically.
Current NCEP ATP III guidelines state that an LDL-C goal of < 70 mg/dL is an
optional goal for patients considered high risk (National Cholesterol Education Program,
2002). This study relates to the current research by showing positive physiological
changes in patients when treatment is more aggressive, thereby confirming the
importance of maintaining patient lipid levels within the recommended guidelines.
Option for improvement. A comorbidity cohort study of hyperlipidemia,
specific to LDL-C levels above 100 mg/dL, was performed over a 24-month period in the
state of Oregon. The study used a group of 6,963 patients with diabetes mellitus. The
study was designed to elucidate qualitative results on patient care using quantitative data
as a measurement of success. The purpose of this study was to determine if a team-based
approach, consisting of a physician and a pharmacist, produced better results at managing
cholesterol levels in diabetic patients. The goal was to achieve an LDL-C of < lOOmg/dL
in diabetic patients.
The study was a 2-year prospective, cluster randomized controlled trial. The
patients were placed into two groups: an intervention group and a control group. The
intervention group was evaluated by physicians and pharmacists, while the control group
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was seen only by physicians. The theoretical framework design produced useful
statistical data that showed a significant difference based on the form of treatment. The
nine clinics involved in the study used the Centricity EMR or electronic medical record to
allow physicians and pharmacists to have the same information about each participant.
The study allowed for new patients to join throughout its duration, which is considered an
open cohort study.
A second analysis was used throughout the duration for those who began and
finished the study without interruption, representing the closed cohort portion of the
study. Patient consent to be a part of the study went through the Providence Primary
Care Research Network (PPCRN) by completing and signing a consent form that had
been reviewed and accepted by the medical and administrative leadership of the study.
All participants from both groups were cared for by 68 physicians in nine
different clinics. The physician would prescribe the treatment determined necessary
based on the patient medical records, lab results, and previous prescriptions. Pharmacist
would evaluate the physician's treatment regimen. The physician would then be
electronically notified by the pharmacist of recommendations. The physician could
choose to ignore, accept, or modify the recommendations. The pharmacist contacted the
patient and informed them of the team-based decision, providing necessary education and
scheduling any necessary lab tests to ensure desired results. All of the communication
from the pharmacist to the participants was via telephone. The information was then
analyzed using descriptive statistics, proportions, means, and ranges. The Rao-Scott test
evaluated the difference between the two groups. The statistics showed a significant
improvement in the control of LDL-C levels in the patients in both groups. In the
intervention group, 78% achieved their target levels, as compared to 50% in the control
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group. The intervention group had an LDL-C level that was 12mg/dL lower than the
control group. In patients with an LDL-C test in the past 12 months, there were 82% that
had reached their goal level compared to 63% in the control group.
This study revealed that high-risk patients with diabetes mellitus and comorbid
coronary heart disease all benefited by using a team-based approach. In the intervention
group, 86% of the high-risk patients reached the LDL-C goal. The impact on long-term
patient outcomes was found to be significant. It was estimated that there could be a 3%
reduction in cardiovascular events over 10 years if sustained lower lipid levels were
achieved in diabetic patients. If applied'to the entire population of the current study with
diabetes mellitus, this could mean that 640 cardiac events could be avoided in the future.
Despite efforts to reduce bias, there was a documented possibility of
contamination bias because the patients selected for the control group of the study
continued using the same physician and pharmacists as before. Although placed in the
control group, these patients were able to obtain education and assistance from the
pharmacist they already had developed a relationship with over years of interaction prior
to the study. In future use of this study, it would be beneficial to use a different group of
physicians and pharmacists for each group of participants.
The study concluded using a team approach significantly lowered levels of LDLC in patients with diabetes mellitus. This study was relevant to the current research
because it demonstrated an alternative means of approaching treatment of individuals
with diabetes mellitus and a risk of cardiovascular disease.

Summary
In conclusion, these literature reviews list the prevalence of dyslipidemia in
diabetic patients and the importance of treating the problem appropriately. Each section
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of literature reviews addressed a different aspect of the problem of dyslipidemia. The
studies discuss the issue of dyslipidemia in diabetic patients, the steps primary care
practitioners are taking at this point, how these steps follow the NCEP ATP III
guidelines, and how the practice of treating these patients could possibly be improved in
the future.

CHAPTER III
Design and Methodology
Dyslipidemia control in type 2 diabetics is a crucial component that primary care
provider's need to regulate. For increased lipid levels in type 2 diabetics the NCEP ATP
III guidelines suggest a LDL-C level < lOOmg/dL, with an optional goal of < 70mg/dL.
The purpose of this study was to evaluate primary care providers' adherence to the
current guidelines and research and the treatment methods they were utilizing.

Population and Sample
The research project design was a quantitative retrospective chart review
conducted in three primary care practice clinics in the southeast region of the U.S. Each
researcher collected 100 charts to perform this study. The population consisted of men
and women between the ages of 18 and 65 years with type 2 diabetes and dyslipidemia.
A sample of participants (N = 300) from the eligible population were reviewed and
utilized for the purpose of this study.

Protection of Human Rights
Prior to conducting this research study, a signed letter of consent was obtained
from the managers of each primary care practice clinics that participated in the study.
The data collection worksheet did not contain any patient identifiers such as patient
name, date of birth, social security number, patient medical, or account number. Such
information was limited to the researchers only. Patient confidentiality was maintained
in accordance with Health Insurance Portability and Accountability Act (HIPAA)
regulations. The researchers ensured that no patient identifying information was removed
from the clinic. The data were compiled and stored on a removable electronic device
with password protection. The collected data were kept by the researchers in a secure
43
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location requiring a key for retrieval. All information was destroyed after the study had
been completed.
Data Collection and Instrumentation
After receiving approval from Mississippi University for Women's Institutional
Review Board (see Appendix B), researchers obtained consent from an authorized
representative from each clinic to begin the data collection process (see Appendix C).
The researchers each selected 100 charts from the medical records at the three primary
care clinics that signed the contract agreement. All charts were chosen starting from
2005 to 2013. Each researcher selected charts according to ICD-9 codes and age
requirements of the study. The researchers collected the data from the medical records
using the data collection worksheet (see Appendix D). The data were collected in the
conference room or break room at the primary care providers' office out of the way of
normal business activity. Data were collected on the age, gender. LDL-C levels, if
therapeutic lifestyle changes were taught to lower LDL-C level, if LDL-C level
medication was prescribed or not, if so which specific lipid-lowering agent was used, and
if a follow-up appointment was established. Data collected were kept in a secure
location where there was no risk of breaking patient confidentiality.
Data Analysis
Descriptive statistics and the chi-square test were used to perform analysis of the
data collected. A simple mathematic equation was used to determine percentages of type
2 diabetic patients who had reached goal LDL-C levels < lOOmg/dL. The data collected
were analyzed to show what percentages of primary care providers are using therapeutic
lifestyle changes, what percentage of patients were placed on lipid-lowering medication,

45
what type of lipid-lowering medications were prescribed, and if follow-up appointments
were scheduled.
Summary
Dyslipidemia in type 2 diabetic patients places them at a higher risk for a
cardiovascular disease and increases their mortality rate. Data were collected and
analyzed to determine if primary care providers were achieving a therapeutic LDL-C
level in type 2 diabetics according to the NCEP ATP III guidelines. This chapter
described the population and sample that were used and how data were collected using
the data' collection worksheet.

CHAPTER IV
Presentation of the Findings
The purpose of this study was to evaluate primary care providers' adherence to
the NCEP ATP III guidelines in the treatment of dyslipidemia in type 2 diabetic patients.
Charts of patients with type 2 diabetes and dyslipidemia who were between the ages of
18 and 65 years were reviewed. A description of the researchers' sample, demographics,
and analysis of the data collected are presented in this chapter.
Description of the Sample
Demographics investigated in this study included age and gender. As shown in
Figure 1, of the 300 participants, the majority were between the ages of 56 and 65 years.
The age group with the least participants, between the ages of 18 and 25 years, only
represented 1% of the total population. The age group between the ages of 26 and 35
years represented 4% of the total population. Sixteen percent were between the ages of
36 and 45 years. Lastly, the age group between the ages of 46 and 55 years represented
28%. As shown in Figure 2, the women made up the majority of participants at 54% (n =
162) of the sample. Men represented 46% (n =138) of the sample population.
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Demographics: Age
1%

m 18-25
m 26-35
36-45
m 46-55
56-65

Figure 1: Representation of age groups related to the study sample (77= 300).

Demographics: Gender

• Male
• Female

Figure 2: Representation of gender related to study sample (N- 300).
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Research Questions
The data collection tool was utilized by each researcher to document findings
from the medical records to determine if (a) LDL-C levels were <100 mg/dL; (b) lipidlowering medications were being prescribed and, if so, which agent; (c) there was a
reason documented for the participants not prescribed lipid-lowering medication; (d)
therapeutic lifestyle changes (TLC) were documented; and (e) a follow-up appointment
was made.
Research question 1. Are primary care providers achieving LDL-C levels < 100
mg/dL in accordance with the NCEP ATP III guidelines for their type 2 diabetic patients?
According to the data analysis, the majority of participants had LDL-C levels > 100
mg/dL. The NCEP ATP III guidelines consider diabetic participants to be a high-risk
equivalent and recommend the goal of LDL-C at < 100 mg/dL. It was revealed through
the data analysis that only 21% (n = 63) of the population were within the goal limit (see
Figure 3).
Research question 2.a. Are primary care providers prescribing lipid-lowering
medications as directed by the NCEP ATP III guidelines? Overall, 88.67% (n = 266) of
the population received lipid-lowering medication. This included 85.71% (n = 54) of
participants with a LDL-C < 100 mg/dL and 89.45% (n = 212) of participants with a
LDL-C level >100 mg/dL. There was no statistically significant difference in
prescription rates between the two groups of participants, ^ (1, 300) = 0.692, p = .406.
Research question 2.b. If a lipid-lowering medication is prescribed, which agent

is utilized? The most commonly prescribed category of medication within the population
studied was statin medications (89.47%). According to the NCEP ATP III guidelines,
statins should be the drug of choice for type 2 diabetics with dyslipidemia.
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i®

<100 mg/dL

« >100 mg/dL

Figure 3: Representation of achievement of LDL-C levels < 100 mg/dL in accordance
with the NCEP ATP III guidelines for type 2 diabetics (N= 300).

Lipid Lowering Medicine

• No
• Yes

Figure 4: Representation of population receiving lipid-lowering medication as directed
by the NCEP ATP III guidelines ( N = 300).
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Lipid Lowering Agent
• Statin
s Bile Acid

Niacin
s Combo
Fibrates

Figure 5: Representation of specific lipid-lowering medications prescribed (N= 300).
Research question 2.c. If a lipid-lowering medication is not prescribed, is there a
documented reason? According to the population studied when a medication was not
prescribed, 55.88% had documentation of a reason.

Lipid Lowering Medicine
m Yes
m No, with Reason
Given
No, without Reason
Given

Figure 6: Representation of available documentation indicating reason to prescribe or not
to prescribe lipid-lowering medication (A 300).
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Research question 3. Are primary care providers documenting patient education
on therapeutic lifestyle changes (TLC)? Of the population studied, 82.33% (n = 247)
received TLC instruction. The presence of this instruction was statistically significantly
higher for participants who had a LDL-C level > 100 mg/dL (84.39%) when compared to
those with a LDL-C level <100 mg/dL (74.60%), x2(fi 300) = 3.276, p = .070.

Figure 7: Representation of TLC instruction for type 2 diabetic patients (N = 300).
Research question 4. Was there a follow-up appointment made? In all cases (N
= 300), a follow-up appointment was made with 100% compliance.
Additional Findings
It should be noted that there were no statistically significant differences identified
based on the following: gender for LDL-C level. r(L 300) = 0.845,p - .358;
prescription rate, xU 300) = 0.037, p - .847; or patient education, jftl, 300) - 0.004, p
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= .951. There is a slight significant difference between gender based on the type of
medication prescribed, x2(l, 300) = 7.893,/? = .096 (see Table 1). Bile acid sequestrants
are used more frequently in men compared with women in this sample.
Table 1
Lipid-lowering Medications Based on Gender Preference (N = 300)

Gender

Statin

Bile Acid

Niacin

Combo

Fibrates

%

Male

87.71

9.06

1.64

0.82

0.82

Female

90.97

2.08

2.78

2.08

2.08

Overall

89.47

5.26

2.26

1.50

1.50

Summary
In this retrospective chart review, the researchers attempted to identify whether
practitioners were following the NCEP ATP III guidelines for the care of type II diabetic
patients with dyslipidemia. A review of 300 charts was performed and the data were
analyzed. Of the participants studied, 79% were not within the goal range of LDL-C in
accordance with the NCEP ATP III guidelines. However, the practitioners did have
88.67% of participants on a lipid-lowering medication, primarily utilizing statins. In only
55.88% of the participants where lipid-lowering medications were not prescribed was
there a compelling reason to forgo this medication regimen. Follow-up appointment rates
were 100%, which was congruent with NCEP ATP III guidelines.

CHAPTER V
Outcomes
The purpose of the study was to evaluate primary care providers' adherence to the
NCEP ATP III guidelines in the treatment of type 2 diabetic patients. According to the
NCEP ATP III guidelines, it is imperative to achieve a LDL-C level < 100 mg/dL (with
an optional goal of < 70 mg/dL) in patients with type 2 diabetes in order to minimize the
risks of cardiovascular complications. In this study, the treatment modalities utilized in
the patient care practices of each primary care provider were reviewed. The use of lipidlowering drugs and education concerning therapeutic lifestyle changes were reviewed.
The researchers also determined whether follow-up appointments were scheduled in
compliance with the current guidelines.
For the purpose of this study, the following questions were posed to evaluate
primary care provider adherence with the NCEP ATP III guidelines for managing
dyslipidemia in the diabetic patient:
1. Are primary care providers achieving LDL-C levels < 100 mg/dL in
accordance with the NCEP ATP III guidelines for their diabetic patients?
2. a. Are primary care providers prescribing lipid-lowering medications as
directed by the NCEP ATP III guidelines?
b. If a lipid-lowering medication is prescribed, what agent is utilized?
c

If a lipid-lowering medication is not prescribed, is there a documented
reason?

3. Are primary care providers documenting patient education on therapeutic
lifestyle changes?
4. Was there a follow up appointment scheduled?
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The sample tor this study consisted of 300 charts collected from three different
primary care clinics in a southeastern state. The charts were chosen based on the
diagnosis of dyslipidemia with type 2 diabetes that were between the ages of 18 and 65
years. The data were collected using a data collection tool (see Appendix C) constructed
by the researchers. The data were analyzed using descriptive statistics and chi-square test
analysis. The current findings are consistent with several of the previous research studies
reviewed in Chapter II. The findings were consistent with current research and showed
that most primary care providers use statin medications to lower type 2 diabetic lipid
levels. One research study indicated that TLC would significantly lower triglyceride
levels and increase weight loss; 82.33% of the findings showed that the primary care
providers were educating the patient on TLC as a method of lowering lipid levels. Data
collected demonstrated that the primary care providers are following the suggested
research methods of educating patients on TLC and primarily utilizing statin medications
as therapy options. The current study correlates a continued need to enforce lowering
LDL-C levels with medication titration and/or the addition of difterent medication
categories.
Interpretation of Findings

The data provided sufficient evidence to suggest that primary care providers are
not reaching the goal LDL-C levels of < 100 mg/dL in diabetic patients per the NCEP
ATP III guidelines. Primary care providers are sufficiently educating their patients on
therapeutic lifestyle changes to aid in lowering their lipid levels. The primary care
providers also reached 100% compliance on scheduling follow-up appointments to assess
lipid levels. The data demonstrated that primary care providers are utilizing the
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guidelines correctly by prescribing statin medications as first-line treatment when
medication is indicated.
Limitations
The limitations noted for this research study included the following: (a) small
sample size, (b) data collection, and (c) type of sampling. Only 300 charts were utilized
for this study, and this small sample size decreases reliability of study results. Collection
of data was from only three primary care clinics in a state located in the southeastern part
of the U.S.; broad generalizability was unable to be attained from a small sample size. A
nonprobability technique, convenience sampling, was chosen to select participants.
Convenience sampling does not provide a true representation of the entire population
because the participants were chosen simply for convenience to the researchers. This
type of sampling has a low external validity because the study cannot be taken and
generalized to an entire population. This nonrandom sampling method decreased
reliability of study results.
Implications and Recommendations
Nola Pender's Theory of Health Promotion was utilized as the theoretical
framework for this study. This theory aided the researchers in determining if primary
care providers are adhering to the NCEP ATP III guidelines and detecting, evaluating,
and treating dyslipidemia in type 2 diabetic patients. After analyzing the data collected,
the researchers noted that the majority of the primary care providers are not proficient in
lowering type 2 diabetics LDL-C level to goal. Primary care providers are educating
these patients on the importance of therapeutic lifestyle changes in compliance with the
guidelines established by the NCEP. According to the data, the providers were efficient
in establishing follow-up appointments.
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Researchers recommendation for this study is to urge primary care providers to
meet the goal of LDL-C level for type 2 diabetics < lOOmg/dL. Out of the 300 charts that
were reviewed, the majority of the patients were on a lipid-lowering medication;
however, lowering the LDL-C level to goal was not being met. Primary care providers
need to titrate the medications according to lower lipid levels to the goal LDL range
recommended by the NCEP ATP III guidelines. Future research should include a larger
sample size. Study participants from a larger geographical region would make the results
of this study more significant and appropriate to a larger population. Also, documenting
the exact reason for not prescribing a lipid-lowering medication to a type 2 diabetic
should be included in future research as these were excluded from the data collection
worksheet.

Conclusions
After completion of this research study, the researchers found valuable
information on the primary care provider's adherence to the NCEP ATP III guidelines on
the treatment of dyslipidemia in type 2 diabetic patients. While the data showed positive
results with ensuring follow-up appointments were scheduled, improvements could still
be made in having complete compliance in lowering their LDL-C levels to goal. The
primary care providers were proficient in educating their patients on therapeutic lifestyle
changes to aid in lowering the LDL-C, along with medication therapy. All of the primary
care providers arranged for follow-up appointments to assess the LDL-C changes from
the therapeutic lifestyle changes or from the medication prescribed.

57

REFERENCES
Becker, D., Gordon, R., Morris. P.. Yorko, J., Gordon, Y., Li. M„ & Iqbal, N. (2008).
Simvastatin vs. therapeutic lifestyle changes and supplements: Randomized
primary prevention trial. Mayo Clinic Proceedings, 83(7), 758-764.
Davidson. M„ Maki, K., Pearson, T., Pasternak, R., Deedwania, P., McKenney, J... . .
Ballantyne, C. (2005). Results of the National Cholesterol Education (NCEP)
Program evaluation project utilizing novel e-technology (NEPTUNE) II survey
and implications for treatment under the recent NCEP Writing Group
recommendations. American Journal of Cardiology, 96(4). 556-563.
Eliasson. B., Svensson, A., Miftaraj, M., Jonasson, J., Eeg-Olofsson, K.. Sundell, K., &
Gudbjornsdottir , S. (2011). Clinical use and effectiveness of lipid-lowering
therapies in diabetes mellitus: An observational study from the Swedish National
Diabetes Register. Plos One, 6(4). 1-9.
Fonseca. V., Handelsman, Y„ & Staels, B. (2010). Colesevelam lowers glucose and lipid
levels in type 2 diabetes: The clinical evidence. Diabetes, Obesity and
Metabolism, 12(5), 384-392.
Free Dictionary. (2012). TheFreeDictionary's medical dictionary. Huntingdon Valley,
PA: Farlex.
George. J. (2011). Nursing theories: The base for professional nursing practice (6 ed.).
Upper Saddle River, NJ: Pearson.
Howard, B. V.. Roman, M.

Deverenx, R. B„ Fleg, J. L„ Galloway, J. M„ Henderson,

j a ,. . . Zhu. J. (2008). Effect of lower targets for blood pressure and LDL

cholesterol on atherosclerosis in diabetes. The SANDS randomized trial. Journal
of American Medical Association, 299(14), 1678-1689.
Kelley, J., Sherrod, R., & Smyth, P. (2009). Coronary artery disease and smoking
cessation intervention. Online Journal of Rural Nursing and Health Care, 9(2),
177-181.
Lynch, J. T., Cooke, C. E., Rosen, J., Gandhi, S., & Bullano, M. F. (2010). Managing
dyslipidemia in primary care with restricted access to lipid-modifying therapy.
American Health and Drug Benefits, 5(3), 340-349.
Murphey, C., & Rew, L. (2009). Three intervention models for exploring oral. Journal
for Specialists in Pediatric Nursing, 14(2), 132-141.
National Cholesterol Education Program. (2002, September). Third report of the National
Cholesterol Education Program (NCEP) expert panel on detection. evaluation,
and treatment of high blood cholesterol in adults. NIH Publication No. 02-5215.
Bethesda, MD: National Heart, Lung, and Blood Institute National Institutes of
Health.
National Diabetes Fact Sheet. (2011). Retrieved from http://ww w.cdc.gov/diabetes/
/pubs/pdf/ndfs2011.pdf
National Institute of Diabetes and Digestive and Kidney Diseases. (2011. February).
Atlanta, GA: National Diabetes Information Clearinghouse. Retrieved from
http://diabetes.niddk.nih.gov/dm/pubs/statistics/

Pender, N„ & Pender, A. (1980). Illness prevention and health promotion services.
American Journal of Public Health, 79(8), 798 803.

Phillips, C., Palmer, C., & Fenwick, J. (2000). Attitude toward nurse practitioners:
Influence of gender, ago, ethnicity, education and income. Journal of the
American Academy of Nurse Practitioners, 12(7), 255-258.
Tohidi, M., Hatami, M., Hadeaegh, F., Safarkhani, M., Harati, H., & Azizi, F. (2010).
Lipid measures for prediction of incident cardiovascular disease in diabetic and
nondiabetic adults: Results of the 8.6 years follow-up of a population-based
cohort study. Lipids in Health & Disease, 9(6). doi: 10.1186/1476-511X-9-6
Toth. P., Zarotsky, V., Sullivan, J., & Laitinen, D. (2009). Dyslipidemia treatment of
patients with diabetes mellitus in a US managed care plan: A retrospective
database analysis. Cardiovascular Diabetology, 5(26), 1-8.
Venes, D. (2009). Diabetes mellitus. Taber's cyclopedic medical dictionary, 21, 630.
Philadelphia, PA: F.A. Davis.

60

APPENDIX A
NCEP ATP III Guidelines
•

Type 2 diabetes is a coronary heart disease (CHD) equivalent and the goal for
target LDL-C is < 100 mg/dL.

•

Therapeutic lifestyle changes (TLC) should be initiated on all diabetic persons
when LDL-C is > 130 mg/dL. In type 2 diabetics, consideration should be given
to simultaneously starting a statin with TLC in those with LDL >130 mg/dL.
Most diabetic persons will require an LDL-lowering drug to obtain the LDL-C
goal of < 100 mg/dL.

•

Statins are the drug of choice and first-line therapy in persons with diabetic
dyslipidemia for lowering LDL-C because they have been proven to be highly
efficacious and well tolerated. Statins have also been proven to reduce the risk
for major coronary events in diabetics. When LDL levels remain above goal after
intervention, the clinician is required to determine the best option for achieving
the goal of < 100 mg/dL. Options include increasing the dose of the LDLlowering drug, adding another LDL-lowering drug (such as a bile acid sequestrant
or fibrate), or maintaining the dose of the LDL-lowering drug and intensifying
TLC.

•

Follow-up is dependent on the previous action by the healthcare provider. A 3month follow-up is advised upon TLC initiation. Upon drug initiation and drug
modification, a 6-week response should be evaluated. Once LDL goal is
achieved, monitoring is recommended every 4-6 months.
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APPENDIX B
Approval of Mississippi University for Women's
Institutional Review Board
Mississippi University
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February 22, 2013

Sueantie Davidson, DNP
Mississippi University for Women
College of Nursing and Speech-Language Pathology
MUW - 910
Columbus, Mississippi 39701-5800
Dear Dr. Davidson:
1 am pleased to inform you that the members of the Institutional Review Board (1KB)
have reviewed the following proposed research and have approved it as submitted:

Name of Study:

Primary Care Management of Type 2 Diabetic
Patients with Dvslipidemia According to
NCEP ATP III Guidelines

Investigators):

Kate Totty, Nancy Grissom, and Shannon
Weathers

Research
Faculty/Advisor:

Sueanne Davidson

I wish vou much success m your research.
Sincerely,

Dan Heimmermann, Ph.D.
Provost and Vice President for Academic Affairs
DH/jh
pc: Tammie McCoy, Institutional Review Board Chairman
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APPENDIX C
Letter of Consent
Date:

SUBJECT: Permission to participate in a research project
I am a graduate student in the family nurse practitioner program at Mississippi University
for Women in Columbus, MS. As a program requirement, we are conducting a quality
assurance research study to assess the dyslipidemia control of diabetic patients in primary
care clinics. We will be assessing the documentation of cholesterol levels, treatment,
follow-up levels, and patient education in diabetic patients. The results of this study will
help heighten health care providers' awareness of NCEP ATP III guidelines in the
management of dyslipidemia in type 2 diabetic patients. The students that are
participating in this research project are Nancy Grissom, Kate Totty, and Shannon
Weathers.
Your participation will involve granting us the privilege of reviewing medical records of
your clients who are 18-65 years of age and have a diagnosis of diabetes (250.0) and
dyslipidemia (272.0). As researchers, we understand that we must maintain the
confidentiality of all information collected from the charts. This information includes,
but is not limited to, all identifying information and research data that we will come into
contact with while performing chart reviews. We agree to refrain from discussing or
disclosing any information regarding your clients. Each researcher will receive HIPPA
and Corporate Compliance training through the facility before beginning the leseaich.
These chart reviews will be recorded on a Data Collection Worksheet. The information
will be entered into a computer data sheet. The data sheet will be saved to a portable
jump drive, which will be kept in a locked area. This area will only be accessible by the
researchers. After completion of the project, all physical data will be destroyed
appropriately. The results of this study may be published, but your name, the clinic, nor
any of the patient's information will be identifiable.
Your participation in this study is strictly voluntary. The possible benefit of your
participation is that the research project will serve as a quality assurance measure for you
The amount of time required for us to review charts and collect data will be
approximately one day. After the research project is complete, we will provide you with
the results from the study.

399-1433. In addition, you may
"time by contacting me or the chair of my research committee.
Sincerely,

63
I have read this letter of consent and have been given the opportunity to ask questions. I
give my consent to participate in the above study.

Primary Care Clinic

Signature

Date
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APPENDIX D
Evaluation of Primary Care Providers' Adherence to NCEP ATP III
Guidelines Data Collection Worksheet

Client
#

1
Age

2
Gender
Man (0)
Woman
(1)

3
Was LDL- C
level
>100mg/dL?
No (0)
Yes (1)

4
Was patient
instructed
on TLC?
No (0)
Yes (1)

5
Is patient
currently on
a lipidlowering
medication?
No (0)
Yes (1)

5A
If yes to #5, what
type of lipidlowering
medication?
Statin (0)
Bile Acid (1)
Niacin (2)
Combo (3)
Fibrates (4)
Other (5)

5B
If no to #5,
was reason
given as to
why
medication
was not
prescribed?
No (0)
Yes (1)

6
Was follow up
appointment
made?
No (0)
Yes (1)

. Vt

'•

